Sams Pharmacy 106203 | |
350 Harbison Blvd, Columbia, South Carolina 29212 | |
(803) 749-4775 |
Name | Sams Pharmacy 106203 |
---|---|
Organization Name | Sams East Inc |
Location | 350 Harbison Blvd, Columbia, South Carolina 29212 |
Type | Durable Medical Equipment & Medical Supplies Supplier |
Phone | (803) 749-4775 |
Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's supplemental new drug application (sNDA) from the U.S. Food and Drug Administration (FDA) for CEFOTAN (cefotetan) for Injection.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.
ROCAWEAR LENDS SUPPORT IN RECLAIMING WOMEN FROM BREAST CANCER. From October 1 through December 31, 2009 Rocawear will donate 5% of the retail price of its special edition Roc for the Cause Polo to Susan G. Komen for the Cure® Circle of Promise with a minimum guaranteed donation of $20,000.
The National Cancer Institute has awarded $11.5 million to Fred Hutchinson Cancer Research Center to lead a five-year, Seattle-based breast cancer research consortium. The goal of the endeavor is to positively impact breast cancer prevention, detection, treatment and care of women who have or are at risk for the disease.
Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.
› Verified 7 days ago
NPI Number | 1497772669 |
Organization Name | SAMS EAST INC |
Doing Business As | SAMS PHARMACY 10-6203 |
Type | Durable Medical Equipment & Medical Supplies Supplier |
Address | 350 Harbison Blvd, Columbia, SC 29212 |
Phone Number | 803-749-4775 |
News Archive
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's supplemental new drug application (sNDA) from the U.S. Food and Drug Administration (FDA) for CEFOTAN (cefotetan) for Injection.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.
ROCAWEAR LENDS SUPPORT IN RECLAIMING WOMEN FROM BREAST CANCER. From October 1 through December 31, 2009 Rocawear will donate 5% of the retail price of its special edition Roc for the Cause Polo to Susan G. Komen for the Cure® Circle of Promise with a minimum guaranteed donation of $20,000.
The National Cancer Institute has awarded $11.5 million to Fred Hutchinson Cancer Research Center to lead a five-year, Seattle-based breast cancer research consortium. The goal of the endeavor is to positively impact breast cancer prevention, detection, treatment and care of women who have or are at risk for the disease.
Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.
› Verified 7 days ago
News Archive
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company's supplemental new drug application (sNDA) from the U.S. Food and Drug Administration (FDA) for CEFOTAN (cefotetan) for Injection.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.
ROCAWEAR LENDS SUPPORT IN RECLAIMING WOMEN FROM BREAST CANCER. From October 1 through December 31, 2009 Rocawear will donate 5% of the retail price of its special edition Roc for the Cause Polo to Susan G. Komen for the Cure® Circle of Promise with a minimum guaranteed donation of $20,000.
The National Cancer Institute has awarded $11.5 million to Fred Hutchinson Cancer Research Center to lead a five-year, Seattle-based breast cancer research consortium. The goal of the endeavor is to positively impact breast cancer prevention, detection, treatment and care of women who have or are at risk for the disease.
Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.
› Verified 7 days ago
Advanced Prosthetics, Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 720 Gracern Rd, Ste # 115, Columbia, South Carolina 29210 Phone: (803) 509-6261 | |
Aids Healthcare Foundation Type: Community/Retail Pharmacy Location: 3025 Farrow Rd, Columbia, South Carolina 29203 Phone: (803) 509-5676 | |
Alala Llc Type: Prosthetic/Orthotic Supplier Location: 3400 Harden Street Ext, Columbia, South Carolina 29203 Phone: (803) 569-4373 | |
Apex Eyecare Type: Medicare Supplier Location: 7499 Parklane Road, Columbia, South Carolina 29223 Phone: (803) 741-7177 | |
Eyecare Center Type: Medicare Supplier Location: 7455 Irmo Dr, Columbia, South Carolina 29212 Phone: (803) 781-2212 |